Free Cash Flow per Share: A measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis. Calculated as: Free Cash Flow / Weighted Average Shares Outstanding (Diluted)
Spero Therapeutics, Inc. (SPRO) had Free Cash Flow per Share of $0.28 for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$0.26M |
|
$-7.20M |
|
-- |
|
$0.26M |
|
$7.80M |
|
$-7.54M |
|
$0.34M |
|
$-7.20M |
|
$-7.20M |
|
$-7.20M |
|
$-7.20M |
|
$-7.20M |
|
$-7.20M |
|
$-7.54M |
|
$-7.54M |
|
57.28M |
|
57.28M |
|
$-0.13 |
|
$-0.13 |
|
| Balance Sheet Financials | |
$57.61M |
|
-- |
|
$1.41M |
|
$59.02M |
|
$5.49M |
|
-- |
|
$0.60M |
|
$6.09M |
|
$52.93M |
|
$52.93M |
|
$52.93M |
|
57.89M |
|
| Cash Flow Statement Financials | |
$15.86M |
|
-- |
|
-- |
|
$40.27M |
|
$56.13M |
|
$15.86M |
|
$1.11M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
10.50 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-2921.71% |
|
-2921.71% |
|
-- |
|
-2791.86% |
|
-2791.86% |
|
$15.86M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
5.86 |
|
15.35 |
|
-13.61% |
|
-13.61% |
|
-12.20% |
|
-13.61% |
|
$0.91 |
|
|
Free Cash Flow per Share |
$0.28 |
$0.28 |
|